Portal hypertensive gastropathy and gastric antral vascular ectasia (GAVE) syndrome

Gut

Volumn 49, Issue 6, 2001, Pages 866-872

  Burak, K W ^a   Lee, S S ^a   Beck, P L ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b Gastrointestinal Research Group   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ESTROGEN; OCTREOTIDE; PROGESTERONE; PROPRANOLOL; SOMATOSTATIN DERIVATIVE; TERLIPRESSIN; VASOPRESSIN;

DISEASE SEVERITY; DRUG MECHANISM; ENDOSCOPY; ESOPHAGUS VARICES; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIVER CIRRHOSIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; STOMACH ANTRUM VASCULAR ECTASIA; STOMACH BLOOD FLOW; STOMACH HEMORRHAGE; STOMACH VARICES;

ADRENERGIC BETA-ANTAGONISTS; ANTIFIBRINOLYTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; ESOPHAGEAL AND GASTRIC VARICES; GASTRIC ANTRAL VASCULAR ECTASIA; GASTROINTESTINAL HEMORRHAGE; GASTROSCOPY; HUMANS; HYPERTENSION, PORTAL; LASER COAGULATION; LIVER CIRRHOSIS; STOMACH DISEASES; TRANEXAMIC ACID;

EID: 0035188667     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.49.6.866     Document Type: Review

References (95)

1. Portal hypertensive gastropathy: Reproducibility of a classification, prevalence of elementary lesions, sensitivity and specificity in the diagnosis of cirrhosis of the liver. A NIEC multicentre study
2. Frequency and factors influencing portal hypertensive gastropathy and duodenopathy in cirrhotic portal hypertension
3. Portal hypertensive gastropathy
4. Factors influencing development of portal hypertensive gastropathy in patients with portal hypertension
5. Stomach in portal hypertension
6. Prevalence of upper and lower gastrointestinal tract findings in liver transplant candidates undergoing screening endoscopic evaluation
7. The effects of transjugular intrahepatic portosystemic shunt on portal hypertensive gastropathy
8. Evaluation of a new endoscopic index to predict first bleeding from the upper gastrointestinal tract in patients with cirrhosis
9. Acute gastrointestinal bleeding from portal hypertensive gastropathy: Prevalence and clinical features
10. Variceal ligation compared with endoscopic sclerotherapy for variceal hemorrhage: Prospective randomized trial
11. Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: Influence on gastropathy, gastric varices and variceal recurrence
12. Changes in portal hypertensive gastropathy after endoscopic variceal sclerotherapy or ligation: An endoscopic observation
13. Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. The New Italian Endoscopic Club for the study and treatment of esophageal varices (NIEC)
14. The natural history of portal hypertensive gastropathy: Influence of variceal eradication
15. Weakness of mucosal barrier in portal hypertensive gastropathy of alcoholic cirrhosis. Effects of propranolol and enprostil
16. Characterization of spontaneous and ethanol-induced gastric damage in cirrhotic rats
17. Hepatic and gastric cytoprotective effects of long-term prostaglandin E1 administration in cirrhotic rats
18. Prostaglandin modulation of the gastric vasculature and mucosal integrity in cirrhotic rats
19. Gastric mucosal prostagtandin E2 levels in cirrhosis and portal hypertension
20. Endogenous prostaglandin E2 in gastric mucosa of patients with alcoholic cirrhosis and portal hypertension
21. Impaired generation of prostaglandins from isolated gastric surface epithelial cells in portal hypertensive rats
22. Reduced gastric mucosal blood flow in patients with portal-hypertensive gastropathy
23. Effects of endoscopic variceal ligation on portal hypertensive gastropathy and gastric mucosal blood flow
24. Gastric mucosal blood flow and hepatic perfusion index in patients with portal hypertensive gastropathy
25. Endoscopic detection of ischaemia with a new probe indicates low oxygenation of gastric epithelium in portal hypertensive gastropathy
26. Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy
27. Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy
28. Reduction of gastric hyperemia by glypressin and vasopressin administration in cirrhotic patients with portal hypertensive gastropathy
29. Effect of bolus injection and continuous infusion of somatostatin on gastric perfusion in cirrhotic patients with portal-hypertensive gastropathy
30. Gastric microcirculatory changes of portal-hypertensive rats can be attenuated by long-term estrogen-progestagen treatment
31. Portal and gastric mucosal hemodynamics in cirrhotic patients with portal-hypertensive gastropathy
32. Diminution in parietal cell number in experimental portal hypertensive gastropathy
33. Helicobacter pylori and congestive gastropathy
34. Helicobacter pylori and congestive gastropathy
35. The effects of Helicobacter pylori colonization on gastric function and the incidence of portal hypertensive gastropathy in patients with cirrhosis of the liver
36. Underlying mechanisms of portal hypertensive gastropathy
37. The role of nitric oxide in portal hypertensive systemic and portal vascular pathology
38. Activity of gastric mucosal nitric oxide synthase in portal hypertensive gastropathy
39. Aminoguanidine corrects hyperdynamic circulation without ameliorating portal hypertension and portal hypertensive gastropathy in anesthetized portal hypertensive rats
40. Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats
41. Tumor necrosis factor-alpha regulates inducible nitric oxide synthase gene expression in the portal hypertensive gastric mucosa of the rat
42. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats
43. Tumor necrosis factor alpha regulates nitric oxide synthase expression in portal hypertensive gastric mucosa of rats
44. Predominant T helper 1 cells in patients with idiopathic portal hypertension
45. The effect of portal hypertension on transforming growth factor-alpha and epidermal growth factor receptor in the gastric mucosa of rats
46. Regional distribution of transforming growth factor-alpha and epidermal growth factor in normal and portal hypertensive gastric mucosa in humans
47. Portal hypertensive gastropathy
48. Effects of propranolol on gastric mucosal perfusion and serum gastrin level in cirrhotic patients with portal hypertensive gastropathy
49. The role of propranolol in congestive gastropathy of portal hypertension
50. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis
51. Somatostatin for acute severe bleeding from portal hypertensive gastropathy
52. Somatostatin reduces gastric mucosal blood flow in patients with portal hypertensive gastropathy: A randomized, double-blind crossover study
53. Chronic administration of octreotide ameliorates portal hypertension and portal hypertensive gastropathy in rats with cirrhosis
54. Somatostatin attenuates the hyperdynamic circulatory state in the gastric mucosa of rats with portal hypertension
55. Vasopressin plus oxygen vs vasopressin alone in cirrhotic patients with portal-hypertensive gastropathy: Effects on gastric mucosal haemodynamics and oxygenation
56. Treatment of bleeding from portal hypertensive gastropathy by portacaval shunt
57. Portal hypertensive gastropathy in noncirrhotic patients. The effect of lienorenal shunts
58. Effects on gastric circulation of treatment for portal hypertension in cirrhosis
59. Radical esophagogastrectomy for unshuntable extrahepatic portal hypertension with bleeding varices: Report of a case
60. Portal hypertensive gastropathy
61. Rebamipide prevents occurrence of gastric lesions following transcatheter arterial embolization in the hepatic artery
62. Gastritis with veno capillary ectasia as a source of massive gastric haemorrhage
63. Gastric antral vascular ectasia: The watermelon stomach
64. Gastric modifications in cirrhosis
65. Severe portal hypertensive gastropathy and antral vascular ectasia are distinct entities in patients with cirrhosis
66. The clinical and endoscopic spectrum of the watermelon stomach
67. The watermelon stomach: Long-term outcome in patients treated with Nd:YAG laser therapy
68. Watermelon stomach
69. Vascular gastric anomalies, CREST syndrome and primary biliary cirrhosis: Efficacy of ethinyl estradiol-norethisterone combination
70. Bleeding from gastric antral vascular ectasia in marrow transplant patients
71. Gastric antral vascular ectasia: A case report and review of the literature
72. Endoscopic laser therapy for watermelon stomach
73. Gastric antral vascular ectasia: A case report of a 10 year follow-up with special consideration of histopathological aspects
74. Gastric antral vascular ectasia in cirrhotic patients: Absence of relation with portal hypertension
75. Antral motility in patients with cirrhosis with or without gastric antral vascular ectasia
76. Gastric mucosal vascular ectasias causing bleeding in cirrhosis. A distinct entity associated with hypergastrinemia and low serum levels of pepsinogen I
77. Neuroendocrine cell proliferations in gastric antral vascular ectasia
78. Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis
79. Diffuse vascular ectasia of the antrum, duodenum, and jejunum in a patient with nodular regenerative hyperplasia. Lack of response to portosystemic shunt or gastrectomy
80. Tranexamic acid for severe bleeding gastric antral vascular ectasia in cirrhosis
81. Successful control of bleeding from gastric antral vascular ectasia (watermelon stomach) by laser photocoagulation
82. Endoscopic laser therapy of the watermelon stomach
83. Endoscopic laser treatment of diffuse gastric antral vascular ectasia
84. Endoscopic laser therapy in a case of gastric antral vascular ectasia (watermelon stomach)
85. Estrogen/progesterone treatment of diffuse antral vascular ectasia
86. Gastric antral vascular ectasia: Maintenance treatment with oestrogen-progesterone
87. Treatment of chronic bleeding from gastric antral vascular ectasia (GAVE) with estrogen-progesterone in cirrhotic patients: An open pilot study
88. Watermelon stomach - An unusual cause of recurrent upper gastrointestinal bleeding in a uremic patient receiving estrogen-progesterone therapy: Case report
89. Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal haemorrhage
90. Gastric antral vascular ectasia (watermelon stomach) - Therapeutic options
91. Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy
92. Diffuse vascular ectasia of the gastric antrum
93. Antral vascular ectasia and scleroderma. Endoscopic, radiologic and anatomopathologic aspects of an uncommon association
94. The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract
95. Unsuccessful octreotide treatment of the watermelon stomach